{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:45:41Z","timestamp":1777902341810,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2019-01721"],"award-info":[{"award-number":["2019-01721"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["CAN2017\/288"],"award-info":[{"award-number":["CAN2017\/288"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["22 2342 Pj"],"award-info":[{"award-number":["22 2342 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.iotech.2026.101585","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:16:06Z","timestamp":1770398166000},"page":"101585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0796-2820","authenticated-orcid":false,"given":"A.","family":"Hahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-7512","authenticated-orcid":false,"given":"S.","family":"Irenaeus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.C.","family":"Sandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wenthe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Jarblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-3637","authenticated-orcid":false,"given":"A.","family":"Schiza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6166-3532","authenticated-orcid":false,"given":"H.","family":"Dahlstrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sundin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-6138","authenticated-orcid":false,"given":"A.","family":"Loskog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-3267","authenticated-orcid":false,"given":"G.J.","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.iotech.2026.101585_bib1","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.iotech.2026.101585_bib2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"issue":"suppl 12","key":"10.1016\/j.iotech.2026.101585_bib3","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.iotech.2026.101585_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.smim.2009.07.001","article-title":"The Janus faces of CD40 in cancer","volume":"21","author":"Loskog","year":"2009","journal-title":"Semin Immunol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101585_bib5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-22-1029","article-title":"CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary","volume":"13","author":"Melero","year":"2023","journal-title":"Cancer Discov"},{"issue":"19","key":"10.1016\/j.iotech.2026.101585_bib6","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101585_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omto.2022.01.003","article-title":"Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition","volume":"24","author":"Wenthe","year":"2022","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"10.1016\/j.iotech.2026.101585_bib8","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s12967-023-04374-2","article-title":"Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models","volume":"21","author":"Wenthe","year":"2023","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.iotech.2026.101585_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.immuni.2008.08.006","article-title":"Mechanisms and consequences of dendritic cell migration","volume":"29","author":"Alvarez","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.iotech.2026.101585_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omto.2021.02.007","article-title":"Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes","volume":"20","author":"Labani-Motlagh","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"7","key":"10.1016\/j.iotech.2026.101585_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18162","article-title":"CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including \u2018find-me\u2019, \u2018eat-me\u2019, and \u2018kill-me\u2019 signalling","volume":"28","author":"Naseri","year":"2024","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.iotech.2026.101585_bib12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12967-016-1037-z","article-title":"Gemcitabine reduces MDSCs, tregs and TGF\u03b2-1 while restoring the teff\/treg ratio in patients with pancreatic cancer","volume":"14","author":"Eriksson","year":"2016","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.iotech.2026.101585_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12094-013-1079-0","article-title":"Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer","volume":"16","author":"Homma","year":"2014","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"10.1016\/j.iotech.2026.101585_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101585_bib15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.iotech.2026.101585_bib16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bjc.2016.42","article-title":"Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients","volume":"114","author":"Loskog","year":"2016","journal-title":"Br J Cancer"},{"issue":"10-11","key":"10.1016\/j.iotech.2026.101585_bib17","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s41417-020-00271-8","article-title":"Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors","volume":"28","author":"Irenaeus","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.iotech.2026.101585_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.iotech.2026.101585_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.iotech.2026.101585_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ijc.32141","article-title":"First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies","volume":"145","author":"Irenaeus","year":"2019","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.iotech.2026.101585_bib21","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","article-title":"Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study","volume":"21","author":"Johnson","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.iotech.2026.101585_bib22","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.iotech.2026.101585_bib23","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.iotech.2026.101585_bib24","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.iotech.2026.101585_bib25","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma\u2014the first phase I\/IIa trial","volume":"16","author":"Malmstr\u00f6m","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:26:39Z","timestamp":1777634799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"alternative-id":["S2590018826000043"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101585","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101585"}}